| |
Baseline
|
Last follow-up
|
|---|
|
Study Group
|
Control Group
|
P-value**
|
Study Group
|
Control Group
|
P-value**
|
|---|
|
Success status
| | |
0.50
| | |
0.28
|
|
Absolute success
|
15 (78.9%)
|
16 (84.2%)
| |
6 (31.6%)
|
10 (52.6%)
| |
|
(maintain status)
|
(5/15)
|
(8/16)
| | | | |
|
(failed)
|
(5/15)
|
(6/16)
| | | | |
|
Qualified success
|
4 (21.1%)
|
3 (15.8%)
| |
7 (36.8%)
|
3 (15.8%)
| |
|
(maintain status)
|
(2/4)
|
(1/3)
| | | | |
|
(failed)
|
(1/4)
|
Zero
| | | | |
|
Failure
|
–
|
–
| |
6 (31.6%)
|
6 (31.6%)
| |
|
Medications
|
|
One or None
|
17 (89.5%)
|
19 (100%)
|
0.24
|
10 (52.6%)
|
15 (78.9%)
|
0.09
|
|
Two or more
|
2 (10.5%)
|
Zero
| |
9 (47.4%)
|
4 (21.1%)
| |
- aData are presented as frequencies (%). Numbers are per eyes
- **P-value calculated using Chi-Square test
